Session Information
Date: Tuesday, November 7, 2017
Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster II
Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
Background/Purpose: Colchicine is the main therapy for familial Mediterranean fever (FMF). However, about 5-10% of FMF patients are colchicine-resistant (1). The reason for colchicine resistance in FMF patients remains obscure. ABO genes are distributed differently among socioeconomic groups, and socioeconomic status is one of the risk factors for disease severity in FMF. To date, no report has evaluated this relation. Our aim was to investigate the association between blood groups and colchicine resistance in FMF patients.
Methods: This is a single-center, cross-sectional study. Between January and December 2016 385 FMF patients were assessed by the Adult and Pediatric Rheumatology outpatient clinics and 297 patients had blood groups (ABO and Rh) results. The blood groups in 1000 volunteer donors who admitted to the Turkish Red Crescent Blood Service in Ankara in 2015 were enrolled as healthy control group. Demographic and clinical data collected for each patient. Response to colchicine was evaluated by two experts (YB and UK). The patients were grouped into two groups: colchicine-responsive patients (Group CR) and colchicine-unresponsive patients (Group CUR).
Results: 297 patients were included in the study. As expected, the acute phase reactants were higher and arthralgia/arthritis, pleuritic chest pain, and erysipelas-like erythema were more frequent in group CUR (p<0.05). FMF patients had frequently blood group “A” than healthy controls (152/297 (51.2%) vs 420/1000 (42.0%), p=0.006). Patients with blood group “A” had 1.5 folds higher FMF compared to “non-A” blood group [OR 1.50 (95% CI 1.11-1.87)], particularly having “A” Rh (+) blood group [OR 1.47 (95% CI 1.13-1.91)]. Furthermore, patients with blood group “A” had a better response to colchicine treatment than “non-A” blood group OR 2.21 (95% CI 1.15-4.27). On the contrary, patients with blood group “0” had prominently associated with unresponsive to colchicine (Table 1).
Table 1. Comparison of blood groups between colchicine unresponsive and responsive familial Mediterranean fever (FMF)a patients
|
ABO / Rh blood group |
Colchicine unresponsive FMFa patients (n=46) |
Colchicine responsive FMFa patients (n=251) |
Odds ratio (95% CI) |
P value |
|
O |
21 (45.7) |
71 (28.3) |
2.12 (1.12-4.04) |
0. 019 |
|
Non- O |
25 (54.3) |
180 (71.7) |
||
|
O Rh (-) |
6 (13.0) |
7 (2.8) |
5.31 (1.69-16.62) |
0.002 |
|
Non- O Rh(-) |
40 (87.0) |
244 (97.2) |
Conclusion: It is well known that blood group A is associated with some of the Cancer such as stomach (2). It may also be related to inflammatory diseases (3). Our results may support associations of blood groups and inflammatory diseases. We demonstrated the blood subgroups and colchicine responses, as well. ABO blood group phenogroups may be used in combination with other risk factors to identify FMF patients at high risk for colchicine resistance.
References
- Gul A. Isr Med Assoc J 2014;16(5):281-284
- Wang Z. Int J Mol Sci 2012;13(10):13308-13321
- Melzer D. PLoS Genet 2008;4(5):e1000072
To cite this abstract in AMA style:
Erden A, Batu ED, Armagan B, Sonmez HE, Sari A, Demir S, Bilgin E, Fırat E, Kilic L, Bilginer Y, Karadag O, Kalyoncu U, Kiraz S. Blood Group ”a“ Was Increased in FMF Patients and Blood Group ”0“ May be Associated with Colchicine Resistance [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/blood-group-a-was-increased-in-fmf-patients-and-blood-group-0-may-be-associated-with-colchicine-resistance/. Accessed .ACR Meeting Abstracts - https://acrabstracts.org/abstract/blood-group-a-was-increased-in-fmf-patients-and-blood-group-0-may-be-associated-with-colchicine-resistance/